Optimal control-based vaccination and testing strategies for COVID-19. 2021

Alberto Olivares, and Ernesto Staffetti
Universidad Rey Juan Carlos Camino del Molino 5, 28942 Fuenlabrada, Madrid, Spain. Electronic address: alberto.olivares@urjc.es.

OBJECTIVE Assuming the availability of a limited amount of effective COVID-19 rapid tests, the effects of various vaccination strategies on SARS-CoV-2 virus transmission are compared for different vaccination scenarios characterized by distinct limitations associated with vaccine supply and administration. METHODS The vaccination strategies are defined by solving optimal control problems of a compartmental epidemic model in which the daily vaccination rate and the daily testing rate for the identification and isolation of asymptomatic subjects are the control variables. Different kinds of algebraic constraints are considered, representing different vaccination scenarios in which the total amount of vaccines available during the time period under consideration is limited or the number of daily available vaccines is limited. These optimal control problems are numerically solved by means of a direct transcription technique, which allows both equality and inequality constraints to be straightforwardly included in the formulation of the optimal control problems. RESULTS Several numerical experiments are conducted, in which the objective functional to be minimized is a combination of the number of symptomatic and asymptomatic infectious subjects with the cost of vaccination of susceptible subjects and testing of asymptomatic infectious subjects. The results confirm the hypothesis that the implementation of early control measures significantly reduces the number of symptomatic infected subjects, which is a key aspect for the resilience of the healthcare system. The sensitivity analysis of the solutions to the weighting parameters of the objective functional reveals that it is possible to obtain a vaccination strategy that allows vaccination supplies to be saved while keeping the same number of symptomatic infected subjects. Furthermore, it indicates that if the vaccination plan is not supported by a sufficient rate of testing, the number of symptomatic infected subjects could increase. Finally, the sensitivity analysis shows that a significant reduction in the efficacy of the vaccines could also lead to a relevant increase in the number of symptomatic infected subjects. CONCLUSIONS The numerical experiments show that the proposed approach, which is based on optimal control of compartmental epidemic models, provides healthcare systems with a suitable method for scheduling vaccination plans and testing policies to control the spread of the SARS-CoV-2 virus.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D014612 Vaccines Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases. Vaccine

Related Publications

Alberto Olivares, and Ernesto Staffetti
March 2021, Journal of theoretical biology,
Alberto Olivares, and Ernesto Staffetti
November 2020, medRxiv : the preprint server for health sciences,
Alberto Olivares, and Ernesto Staffetti
January 2021, Nature communications,
Alberto Olivares, and Ernesto Staffetti
December 2022, Physica A,
Alberto Olivares, and Ernesto Staffetti
August 2021, Studies in applied mathematics (Cambridge, Mass.),
Alberto Olivares, and Ernesto Staffetti
January 2022, SN computer science,
Alberto Olivares, and Ernesto Staffetti
December 2020, Journal of biological dynamics,
Alberto Olivares, and Ernesto Staffetti
January 2020, Scientifica,
Alberto Olivares, and Ernesto Staffetti
October 2021, Scientific reports,
Alberto Olivares, and Ernesto Staffetti
August 2023, Human vaccines & immunotherapeutics,
Copied contents to your clipboard!